La vendita allo scoperto per Phathom Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Phathom Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Phathom Pharmaceuticals (NASDAQ:PHAT) Azioni, Report sulle vendite allo scoperto

Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals Inc

WIIM

Sweetgreen shares are trading lower after the company reported worse-than-expected Q3 financial results.

GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.67 by 46.27 percent. This is a 66.1 percent increase over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $303.316 million which beat the analyst consensus estimate of $279.570 million by 8.49 percent. This is a 70.24 percent increase over sales of $178.167 million the same period last year.

Earnings

Earnings Beats

News

GigaCloud Tech Q3 2024 GAAP EPS $0.98 Beats $0.67 Estimate, Sales $303.316M Beat $279.570M Estimate

ACVA

ACV Auctions shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance.

Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) reported quarterly earnings of $0.47 per share which missed the analyst consensus estimate of $0.52 by 9.62 percent. The company reported quarterly sales of $112.771 million which missed the analyst consensus estimate of $112.933 million by 0.14 percent. This is a 6.86 percent increase over sales of $105.528 million the same period last year.

Earnings Misses

Karat Packaging Q3 2024 Adj. EPS $0.47 Misses $0.52 Estimate, Sales $112.771M Miss $112.933M Estimate

Ovintiv Q3 EPS $1.92

Income Opportunity Realty Q3 EPS $0.29 Down From $0.39 YoY

CARG

CarGurus shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance and Q4 adjusted EPS guidance above estimates.

General

NVNI

Nvni Group Limited Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

EMX Royalty Q3 Sales $7.03M Down From $12.93M YoY

Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.64 percent decrease over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $165.00 thousand which beat the analyst consensus estimate of $80.00 thousand by 106.25 percent. This is a 17.02 percent increase over sales of $141.00 thousand the same period last year.

CRDF

Cardiff Oncology Q3 EPS $(0.25) Beats $(0.27) Estimate, Sales $165.00K Beat $80.00K Estimate

Biotech

ELTX

Elicio Therapeutics Shares ELI-002 Phase 1 Data At SITC 2024; Preliminary Results Show Dose-Dependent T Cell Responses Targeting KRAS Mutations And Link To Disease-Free Survival

Abacus Life (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.14 by 42.86 percent. The company reported quarterly sales of $28.148 million which missed the analyst consensus estimate of $28.461 million by 1.10 percent. This is a 33.27 percent increase over sales of $21.121 million the same period last year.

Abacus Life Q3 2024 Adj. EPS $0.20 Beats $0.14 Estimate, Sales $28.148M Miss $28.461M Estimate

EPRX

Eurpaxia Pharmaceuticals Q3 EPS $(0.17) Up From $(0.18) YoY

CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.17) by 141.18 percent. The company reported quarterly sales of $33.432 million which beat the analyst consensus estimate of $17.514 million by 90.88 percent. This is a 26.71 percent increase over sales of $26.384 million the same period last year.

CTMX

CytomX Therapeutics Q3 2024 GAAP EPS $0.07 Beats $(0.17) Estimate, Sales $33.432M Beat $17.514M Estimate

ALRM

Alarm.com shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 guidance.

Management

REZI

Resideo Unveils CEO Succession Plan As Jay Geldmacher Prepares To Retire In 2025; Vice-Chair Andrew C. Teich Named Next Chairman

Ever feel like the CBD market is on autopilot, stuck in a cycle of repetitive products and shrinking profit margins? For cannabis investors, this stuck-on-repeat dynamic has meant intense price pressure and dwindling returns.
Jaunty's CEO Nicolas Guarino knows a thing or two about survival. Before navigating the brutal CBD crash that slashed prices by 99%, he and his family weathered the economic and political upheaval of Chávez-era Venezuela. Now, in an industry dominated by dull uniformity, Guarino has led Jaunty to profitability by leaning into solventless products and creating an accessible, unpretentious brand.
Guarino's journey offers a fresh perspective and a profitable path forward for investors seeking stability in the face of volatility, proving that resilience is an asset that translates across borders and markets.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h2 class="wp-block-heading">Adiós  Chavez!</h2>
Guarino's roots are firmly planted in agriculture. He grew up working with water buffalo on family farms in southeastern <a href="https://www.benzinga.com/markets/cannabis/24/07/40068000/cannabis-legalization-in-venezuela-can-maduro-follow-colombias-lead-amid-political-upheaval-and-">Venezuela's </a>grassy savannah. Moving to New York for college, he brought with him the ethos of hard work and family ties. This background profoundly shaped his journey into the cannabis industry.
"Our family has always been about getting our hands dirty," Guarino told Benzinga Cannabis in an exclusive interview. "The values I learned back on the farm have been foundational in building Jaunty. It's about understanding the land, the crop, and the entire process, which, in turn, influences our approach to quality cannabis production."
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="768" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131239/IMG_1993-1024x768.jpeg" alt="" class="wp-image-633434" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131239/IMG_1993-1024x768.jpeg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131239/IMG_1993-300x225.jpeg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131239/IMG_1993-768x576.jpeg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131239/IMG_1993.jpeg 1440w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Courtesy of Jaunty</figcaption></figure>
<h2 class="wp-block-heading">CBD Market Carash And Escape From Commoditization</h2>
Entering the CBD space in 2017, Guarino and his team launched Jaunty as a producer and supplier of high-quality CBD oil for manufacturers across the U.S. However as the market became saturated, they quickly encountered the harsh realities of price compression. By 2020, Jaunty saw the<a href="https://www.benzinga.com/markets/cannabis/24/10/41147420/congressional-bill-is-game-changer-for-cbd-regulation-its-long-overdue-says-hemp-coalition"> price of CBD oil drop</a> to a meager $65 per kilo &#8211; a 99% decline from its peak, putting intense pressure on their wholesale business model.
&#8220;The CBD space became a game of scale,&#8221; Guarino explained. &#8220;The <a href="https://www.benzinga.com/markets/cannabis/24/10/41406637/top-5-cannabis-legalization-missteps-in-recent-u-s-history-a-selection">Farm Bill's structure</a> supports large-scale production but doesn't leave much room for smaller, quality-focused brands. We were nearly <a href="https://www.benzinga.com/markets/cannabis/24/10/41283230/epic-cannabis-fails-you-should-know-about-medmen-eaze-and-others-go-down-in-california-meltdowns">bankrupt,</a> but we couldn't quit. We saw an opening when New York moved towards recreational legalization.&#8221;
New York's decision to prioritize licenses for existing CBD operators was a lifeline. Guarino realized that to thrive in the THC market, Jaunty needed a brand that could stand apart, rather than relying on wholesale production alone. "It was clear we had to create a brand that would resonate on quality and effect," he said.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/11/41780079/floridas-cannabis-initiative-defeated-trulieve-ceo-kim-rivers-nfls-ricky-williams-and-others-res"> Florida&#8217;s Cannabis Initiative Defeated: Trulieve CEO Kim Rivers, NFL&#8217;s Ricky Williams And Others Respond</a>
<h3 class="wp-block-heading">Building Jaunty: It's The Brand, Not Just The Product</h3>
When THC legalization got underway in New York, Guarino initially entertained deals with established brands like Old Pal, almost venturing into co-branding and white labeling. But he soon realized that these arrangements would pull Jaunty back into the commodity cycle he had just escaped.
"White labeling is for big facilities, with massive automation," he said. "We don't have that; we have exceptional extraction skills honed over years in <a href="https://www.benzinga.com/topic/hemp">CBD</a>. So, we decided to focus on <a href="https://www.benzinga.com/topic/cannabis-marketing">creating our brand rather than becoming just another supplier</a>."
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="819" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131331/Jaunty-Group-shot-with-all-9-carts-1024x819.jpg" alt="" class="wp-image-633437" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131331/Jaunty-Group-shot-with-all-9-carts-1024x819.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131331/Jaunty-Group-shot-with-all-9-carts-300x240.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131331/Jaunty-Group-shot-with-all-9-carts-768x614.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131331/Jaunty-Group-shot-with-all-9-carts.jpg 1350w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Courtesy of Jaunty</figcaption></figure>
This strategic decision led to the creation of Jaunty's product lines, starting with vapes and expanding to solventless Live Rosin Gummies. By prioritizing brand identity, Jaunty has been able to maintain a competitive edge in a market where differentiation is essential.
<h3 class="wp-block-heading">The Fam Behind The Brand</h3>
Jaunty's operations are more than just a business for Guarino, they are a family effort. He brought in his cousin from Venezuela who is a seasoned logistics expert, to run Jaunty's distribution. His cousin's experience managing 75 poultry trucks across Venezuela in challenging conditions was invaluable.
"With him overseeing our logistics, we are the only company in New York that guarantees delivery within 48 hours," Guarino said. "It's truly a blessing to have someone so experienced managing a crucial part of the business." This expertise has allowed Jaunty to achieve an impressively low 4.3% distribution cost relative to sales, enhancing profitability without sacrificing service quality.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/11/41775784/hemp-vs-marijuana-industry-tensions-rise-amid-rejection-of-cannabis-legalization-in-florida-the-"> Hemp Vs. Marijuana: Industry Tensions Rise Amid Rejection Of Cannabis Legalization In Florida, The Dakotas</a>
<h3 class="wp-block-heading">A Few Cost-Effective Strategies</h3>
The decision to invest in butane <a href="https://www.benzinga.com/markets/cannabis/24/11/41760263/marijuana-growing-solution-provider-agrify-gets-20m-boost-from-green-thumb-to-power-up-cannabis-">extraction for specific products </a>reflects Jaunty&#8217;s calculated approach to innovation. &#8220;The full investment for our butane machine setup was around $500,000,&#8221; Guarino explained. &#8220;But with the right brand presence and strong distribution, we project a return on investment in four to five months."&nbsp;
Jaunty now places a strong emphasis on solventless products, reflecting an industry-wide shift towards purer, more natural cannabis experiences. According to Guarino, solventless extraction is a cost-effective method with high market appeal, particularly since it requires less investment compared to butane-based extraction.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131412/8-1024x683.jpg" alt="" class="wp-image-633438" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131412/8-1024x683.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131412/8-300x200.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131412/8-768x512.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131412/8-1536x1024.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131412/8.jpg 1620w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Courtesy of Jaunty</figcaption></figure>
"It's a lower capex approach that lets us offer high-quality products without the heavy initial investment," he said. In addition, by focusing on outdoor-grown cannabis, Jaunty has been able to keep costs low while achieving quality results comparable to indoor-grown products.
<h3 class="wp-block-heading">A Consumer-Centric Identity</h3>
Jaunty aims to create an accessible brand for cannabis users interested in oil-based products, especially those curious about moving from flower or nicotine vaping to cannabis oils.&nbsp;
Unlike many <a href="https://www.benzinga.com/topic/cannabis-branding">extract-focused brands</a>, which can feel exclusive or elitist, Jaunty's approach is deliberately welcoming. "Too many brands make consumers feel they aren't in the know. Jaunty is here to open up cannabis, not gatekeep it," Guarino said.
This inclusive identity is especially appealing to nicotine vapers exploring cannabis, with Jaunty offering an approachable entry point.&nbsp;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41764503/nebraska-says-yes-to-medical-cannabis-after-years-of-failed-legalization-attempts-heres-what-you">Nebraska Says Yes To Medical Cannabis After Years Of Failed Legalization Attempts: Here&#8217;s What You Need To Know</a>
<h3 class="wp-block-heading">&#8216;The Dab Crowd&#8217;</h3>
&#8220;Most extract-focused brands have a vibe like, ‘If you know, you know.' If you&#8217;re not part of the dab crowd, you're not cool enough," he added, highlighting how Jaunty takes the opposite approach by making cannabis feel approachable and not intimidating.
To help new users feel informed, Jaunty prioritizes consumer education, explaining oil types, effects, and product benefits in their packaging and interactions. "We take every opportunity to educate—about oil types, effects, and why you might choose one product over another," Guarino explained.
As they continue to grow, Jaunty is actively learning about its consumer base, even incorporating QR code surveys on packaging to gather direct feedback.&nbsp;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="807" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131438/Jaunty-Dreamberry-gummies-10-pack-creative-shot-color-pop-background-prop-with-fruit-1024x807.jpg" alt="" class="wp-image-633439" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131438/Jaunty-Dreamberry-gummies-10-pack-creative-shot-color-pop-background-prop-with-fruit-1024x807.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131438/Jaunty-Dreamberry-gummies-10-pack-creative-shot-color-pop-background-prop-with-fruit-300x236.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131438/Jaunty-Dreamberry-gummies-10-pack-creative-shot-color-pop-background-prop-with-fruit-768x605.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06131438/Jaunty-Dreamberry-gummies-10-pack-creative-shot-color-pop-background-prop-with-fruit.jpg 1370w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Courtesy of Jaunty</figcaption></figure>
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/10/41521360/8b-market-on-the-brink-texas-senator-calls-it-uncontrollable-proposes-erasing-hemp"> $8B Market On The Brink: Texas Senator Calls It &#8216;Uncontrollable,&#8217; Proposes Erasing Hemp</a>

Cannabis

Market Summary

Entrepreneurship

Retail Sales

Economics

Success Stories

Startups

Small Business

Exclusives

Markets

Tech

Interview

EXCLUSIVE: Surviving Chavez's Venezuela To CBD Crash - CEO Reveals How To Profit In A Market Stuck On Repeat

Tidewater shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue below estimates.

American Realty Investors Q3 EPS Sales $11.607M Down From $12.526M YoY

Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.52 by 13.46 percent. The company reported quarterly sales of $404.530 million which beat the analyst consensus estimate of $400.423 million by 1.03 percent. This is a 2.21 percent increase over sales of $395.799 million the same period last year.

Pebblebrook Hotel Q3 2024 FFO $0.59 Beats $0.52 Estimate, Sales $404.530M Beat $400.423M Estimate

Short-squeeze opportunities are tough to find. Combine market timing with fundamentals for these stocks.

These Are The Top 3 Most-Shorted Stocks In August 2024; Here's Why

Analyst Joseph Stringer from Needham maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) and keeping the price target at $2...

Phathom Pharmaceuticals' V oquezna: A Rising Star in GERD Treatment Market

Joseph Stringer, an analyst from Needham, maintained the Buy rating on Phathom Pharmaceuticals (PHAT – Research Report). The associated price targe...

Phathom Pharmaceuticals' V oquezna Shows Promising Market Penetration and Drives Buy Rating

Following Up On Phathom Pharmaceuticals

Buy Rating for Phathom Pharmaceuticals Amid Strong Voquezna Prescription Growth

Needham analyst Joseph Stringer maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today and set a price target of $26.00....

Buy Rating Affirmed: Phathom Pharmaceuticals' V oquezna Shows Promising Market Penetration and Growth Potential

Phathom's Voquezna: A Breakthrough Drug Facing Marketing Challenges

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today. The company's shares cl...

Phathom Pharmaceuticals (PHAT) Gets a Buy from Craig-Hallum

Phathom Pharmaceuticals GAAP EPS of -$1.32 beats by $0.21, revenue of $16.4M beats by $3.99M

In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report), with a price ...

Phathom Pharmaceuticals Surpasses Expectations: Strong Q3 Performance and Bullish Outlook Drive Increased Revenue Estimates and Price Target

BYND

GRPN

PHAT

Press Releases

Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

Health Care

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Comments

Phathom Pharmaceuticals

Vendite allo scoperto

Phathom Pharmaceuticals (NASDAQ:PHAT) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO